The Flagship Pioneering spinout uses permanent bonds to target shallow pockets, drastically expanding the druggable universe for small molecules.
Attaching amino acids to a hydrophobic organic molecule allows them to self-assemble into rare, knotted structures with ...
2.5-dimensional cell growth approaches, enhanced by plasmas, are the likely future for applications in medicine and ...
I'll take the H2O and Flora 5, thank you ...
The biopharmaceutical sector is transitioning from reactive off-line quality control to a proactive quality by design (QbD) framework. Process analytical technology (PAT) enables this shift through ...
Biotium’s ViaTag™ Haloalkane Ligands deliver bright, durable labeling that remains robust through fixation, permeabilization, ...
Live for the Outdoors on MSN
We went for a walk around Britain’s worst-selling OS map – surely it can’t be as bad as it sounds?
Can there possibly be a great walk on Britain’s worst-selling Ordnance Survey Explorer map? That’s a question we were only ...
Terremoto Biosciences is a company making waves in the drug development world. They’re using a pretty cool approach to create new medicines, focusing on how molecules interact at a chemical level.
Defining precisely where drugs engage their targets in vivo is essential for understanding efficacy and toxicity. However, mapping in vivo drug targets with spatial and cellular resolution remains ...
Eli Lilly and Company (NYSE:LLY) executives highlighted strong 2025 performance, continued demand for its incretin medicines, ...
Henniker Plasma announces the launch of CoatX®, an advanced plasma-coating technology designed to deliver permanent, ...
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth-quarter of 2025 and provided 2026 financial guidance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results